Evidence map›Paper›PMID 35456622›Full record

ArticlePharmaceutics2022

Selective Anticancer Therapy Based on a HA-CD44 Interaction Inhibitor Loaded on Polymeric Nanoparticles.

José M Espejo-Román, Belén Rubio-Ruiz, Victoria Cano-Cortés, Olga Cruz-López, Saúl Gonzalez-Resines, Carmen Domene, Ana Conejo-García, Rosario M Sánchez-Martín

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. An Overview of Antitumour Activity of Polysaccharides.Molecules (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

José M Espejo-RománDepartment of Medicinal and Organic Chemistry and Excellence Research Unit of Chemistry Applied to Biomedicine and the Environment, Faculty of Pharmacy, Campus Cartuja s/n, University of Granada, 18071 Granada, Spain.ORCID 0000-0002-3231-1095
Belén Rubio-RuizDepartment of Medicinal and Organic Chemistry and Excellence Research Unit of Chemistry Applied to Biomedicine and the Environment, Faculty of Pharmacy, Campus Cartuja s/n, University of Granada, 18071 Granada, Spain.ORCID 0000-0003-4720-6578
Victoria Cano-CortésDepartment of Medicinal and Organic Chemistry and Excellence Research Unit of Chemistry Applied to Biomedicine and the Environment, Faculty of Pharmacy, Campus Cartuja s/n, University of Granada, 18071 Granada, Spain.
Olga Cruz-LópezDepartment of Medicinal and Organic Chemistry and Excellence Research Unit of Chemistry Applied to Biomedicine and the Environment, Faculty of Pharmacy, Campus Cartuja s/n, University of Granada, 18071 Granada, Spain.
Saúl Gonzalez-ResinesDepartment of Chemistry, University of Bath, Claverton Down, Bath BA2 7AX, UK.
Carmen DomeneDepartment of Chemistry, University of Bath, Claverton Down, Bath BA2 7AX, UK.ORCID 0000-0001-7115-4232
Ana Conejo-GarcíaDepartment of Medicinal and Organic Chemistry and Excellence Research Unit of Chemistry Applied to Biomedicine and the Environment, Faculty of Pharmacy, Campus Cartuja s/n, University of Granada, 18071 Granada, Spain.ORCID 0000-0001-5776-7315
Rosario M Sánchez-MartínDepartment of Medicinal and Organic Chemistry and Excellence Research Unit of Chemistry Applied to Biomedicine and the Environment, Faculty of Pharmacy, Campus Cartuja s/n, University of Granada, 18071 Granada, Spain.
Universidad de Granada · ESUniversity of Bath · GBUniversity of Oxford · GB

Funding

Andalusian Regional Government PAIDI-TC-PVT-PSETC-2.0.Andalusian Regional Government POSTDOC_21_00118Biotechnology and Biological Sciences Research Council BB/L01386X/1Consejería de Economía, Conocimiento, Empresas y Universidad of the Junta de Andalucía P18-RT-1679 , PT18-TP-4160 and B-FQM-475-UGR18EPSRC EP/L000253/1European Union's Horizon 2020 Research and Innovation Program Marie Sklodowska-Curie Grant Agreement no. 754446Health Institute Carlos III DTS18/00121Research Results Transfer Office (OTRI) of the University of Granada PR/17/006Spanish Ministry of Economy and Competitiveness PID2019.110987RB.I00Spanish Ministry of Education FPU 16/02061UGR Research and Knowledge Transfer Fund Athenea3i
6 · The paper itself

Abstract

Hyaluronic acid (HA), through its interactions with the cluster of differentiation 44 (CD44), acts as a potent modulator of the tumor microenvironment, creating a wide range of extracellular stimuli for tumor growth, angiogenesis, invasion, and metastasis. An innovative antitumor treatment strategy based on the development of a nanodevice for selective release of an inhibitor of the HA-CD44 interaction is presented. Computational analysis was performed to evaluate the interaction of the designed tetrahydroisoquinoline-ketone derivative (

Indexed as

anticancer therapycluster of differentiation 44hyaluronic acidmolecular dynamics simulationsnanomedicineselective releasetetrahydroisoquinoline

Identifiers

PMID35456622
PMCPMC9032636
OpenAlexW4224080993

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.